ACTUALITES

SEMINARS

  • CRCL/CLB Seminar

The next CRCL/CLB seminar will take place Friday the 21st of Fébruary at 11.30am in the ONCORA meeting room (Centre Léon Bérard, 2nd floor).
We are pleased to welcome
Cédric Allier (Univ. Grenoble Alpes, CEA, LETI, DTBS, LSIC, F‐38000 Grenoble, France) for a seminar about :
"Video lens-free microscopy of cell cultures: from 2D to 3D"

SCIENTIFIC EVENTS

  • 2nd Symposium IRCI - 8th to 10th June, 2020, Lyon, France


The Cancer Research Center of Lyon and the International Center for Infectiology Research coorganize the 2nd International Symposium on Immune Responses in Cancer and Infection (IRCI).
The event will be held from the 8th to the 10th of June, 2020 in Lyon, France.

IRCI is an international conference that occurs every three years with talks from experts in the field of immune responses in cancer and infection. This meeting is a unique chance for you to learn, exchange, and expose your results in a world class setting in which registration prices have been kept low.

Call for paper and early bird registration until march 31st on https://irci2020.insight-outside.fr/

OTHER

LATEST PUBLICATIONS

  • Netrin-1 promotes naive pluripotency through Neo1 and Unc5b co-regulation of Wnt and MAPK signalling

In mouse embryonic stem cells (mESCs), chemical blockade of Gsk3α/β and Mek1/2 (2i) instructs a self-renewing ground state whose endogenous inducers are unknown. Here we show that the axon guidance cue Netrin-1 promotes naive pluripotency by triggering profound signalling, transcriptomic and epigenetic changes in mESCs. Furthermore, we demonstrate that Netrin-1 can substitute for blockade of Gsk3α/β and Mek1/2 to sustain self-renewal of mESCs in combination with leukaemia inhibitory factor and regulates the formation of the mouse pluripotent blastocyst. Mechanistically, we reveal how Netrin-1 and the balance of its receptors Neo1 and Unc5B co-regulate Wnt and MAPK pathways in both mouse and human ESCs. Netrin-1 induces Fak kinase to inactivate Gsk3α/β and stabilize β-catenin while increasing the phosphatase activity of a Ppp2r2c-containing Pp2a complex to reduce Erk1/2 activity. Collectively, this work identifies Netrin-1 as a regulator of pluripotency and reveals that it mediates different effects in mESCs depending on its receptor dosage, opening perspectives for balancing self-renewal and lineage commitment.

https://doi.org/10.1038/s41556-020-0483-2

  • Nature Communications

Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA r

Hepatitis Delta virus (HDV) is a satellite of Hepatitis B virus with a single-stranded circular RNA genome. HDV RNA genome synthesis is carried out in infected cells by cellular RNA polymerases with the assistance of the small hepatitis delta antigen (S-HDAg). Here we show that S-HDAg binds the bromodomain (BRD) adjacent to zinc finger domain 2B (BAZ2B) protein, a regulatory subunit of BAZ2B-associated remodeling factor (BRF) ISWI chromatin remodeling complexes. shRNA-mediated silencing of BAZ2B or its inactivation with the BAZ2B BRD inhibitor GSK2801 impairs HDV replication in HDV-infected human hepatocytes. S-HDAg contains a short linear interacting motif (SLiM) KacXXR, similar to the one recognized by BAZ2B BRD in histone H3. We found that the integrity of the S-HDAg SLiM sequence is required for S-HDAg interaction with BAZ2B BRD and for HDV RNA replication. Our results suggest that S-HDAg uses a histone mimicry strategy to co-activate the RNA polymerase II-dependent synthesis of HDV RNA and sustain HDV replication.

https://doi.org/10.1038/s41467-020-14299-9

  • Science Translational Medicine

Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade.

Although immune checkpoint–targeted therapies are currently revolutionizing cancer care, only a minority of patients develop durable objective responses to anti–PD-1, PD-L1, and CTLA-4 therapy. Therefore, new therapeutic interventions are needed to increase the immunogenicity of tumors and overcome the resistance to these immunotherapies. Oncolytic properties of common viruses can be exploited for the priming of antitumor immunity, and such oncolytic viruses are currently in active clinical development in combination with immune checkpoint–targeted therapies.

> MORE INFORMATION

DOI: 10.1126/scitranslmed.aat5025

  • LKB1 specifies neural crest cell fates through pyruvate-alanine cycling

Résultat de recherche d'images pour 'science advances' Metabolic Processes underlying the development of the neural crest, an embryonic population of multipotent migratory cells, are poorly understood. Here, we report that conditional ablation of the Lkb1 tumor suppressor kinase in mouse neural crest stem cells led to intestinal pseudo-obstruction and hind limb paralysis. This phenotype originated from a postnatal degeneration of the enteric nervous ganglia and from a defective differentiation of Schwann cells. Metabolomic profiling revealed that pyruvate-alanine conversion is enhanced in the absence of Lkb1. Mechanistically, inhibition of alanine transaminases restored glial differentiation in an mTOR-dependent manner, while increased alanine level directly inhibited the glial commitment of neural crest cells. Treatment with the metabolic modulator AICAR suppressed mTOR signaling and prevented Schwann cell and enteric defects of Lkb1 mutant mice. These data uncover a link between pyruvate-alanine cycling and the specification of glial cell fate with potential implications in the understanding of the molecular pathogenesis of neural crest diseases.
DOI : 10.1126/sciadv.aau5106

JOB OPPORTUNITIES

  • May 2020 - PhD Position
IMPORTANT : you must apply online

PhD position at the CRCL, Lyon M/F "characterisation of the role of netrine-1 in the resistance and plasticity in humain colorectal cancers (P. Mehlen’s team)
https://emploi.cnrs.fr/Offres/Doctorant/UMR5286-BLABRU-003/Default.aspx?lang=EN

Ensure that your candidate profile is correct before applying. Your profile information will be added to the details for each application. In order to increase your visibility on our Careers Portal and allow employers to see your candidate profile, you can upload your CV to our CV library in one click!
  • March 2020 - Lab manager position

L’équipe « Régulation moléculaire de l’Immunité dans le Cancer » recherche un(e) candidat(e) motivé(e) pour un poste de Lab Manager (Technicien, Assistant Ingénieur ou Ingénieur d’Etudes).
Consulter l'offre

  • February 2020 - Post-doctoral position

A post-doctoral position is now available in the team of Dr. Gabriel Ichim. 
The main focus of the team is studying mitochondrial regulation of cell death and non-lethal caspase activation with a wide-range of implication in cancer cell invasiveness, resistance to therapy or cancer stem cells.
More information

  • January 2020 - Post-doctoral position

The laboratory of Dr. Julien C. Marie is seeking an experienced, creative and autonomous post-doctoral fellow to study the effects of TGF-B on T cell-biology.
More information

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :